Critical Milestones Achieved Ahead Of Schedule In Lung Cancer Study
![CL_Critical Milestones-Lung Cancer Case Study CL_Critical Milestones-Lung Cancer Case Study](https://vertassets.blob.core.windows.net/image/fb98e31a/fb98e31a-c9c6-43bd-8e08-4eafa75a28e2/375_250-cl_critical_milestones_lung_cancer_case_study.jpg)
IQVIA™ Biotech was selected by a biotechnology company preparing to launch an international Phase III clinical trial for its investigational anaplastic lymphoma kinase (ALK) inhibitor in patients with non-small cell lung cancer (NSCLC). As this was a highly competitive space with more than five companies pursuing the same market, the sponsor’s clinical operations team was seeking an oncology-focused partner who could support protocol design and accelerate the start-up process to meet enrollment milestones quickly. IQVIA Biotech’s oncology team leveraged our extensive NSCLC operational experience, global footprint, and strategic resources to execute this large Phase III study.
Following a competitive review, the sponsor selected IQVIA Biotech to lead the study, managing Europe and Asia, while the sponsor managed North America (NA) in-house. This case study will focus on the ex-NA portion of the clinical trial covering more than 100 sites across nearly 20 countries.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.